Who
Duarte Ira
EVP, Chief Financial Officer
Company insider
Files Form 4 as: EVP, Chief Financial Officer, Heron Therapeutics; Director, TerrAscend; Principal Accounting Officer, Cornerstone Therapeutics.
In numbers
- Trades disclosed
- 93
- Buys
- 1
- Sells
- 0
- Bought
- $76K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 2 Mar 2011
- Last trade
- 19 Oct 2026
- Last filed
- 21 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 21 Oct 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,874 | filing |
| 19 Oct 2026filed 21 Oct 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $3971,102 at $0.36 | filing |
| 19 Oct 2026filed 21 Oct 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,874 at $0.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,694 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,694 at $0.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,6633,326 at $0.50 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,694 at $0.00 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,694 | filing |
| 31 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,6633,326 at $0.50 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —13,535 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,9253,850 at $0.50 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,535 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,535 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —13,535 | filing |
| 30 Jul 2026filed 3 Aug 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,9253,850 at $0.50 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,874 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code F | $5171,101 at $0.47 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,874 at $0.00 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,874 at $0.00 | filing |
| 19 Jul 2026filed 20 Jul 2026 | HRTX Heron TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,874 | filing |
News
No headline names them, or the companies they trade most, lately.